~~<i id='ED81C862AB'><strike id='ED81C862AB'><tt id='ED81C862AB'><pre id='ED81C862AB'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

knowledge

author：leisure time 2025-09-28 23:44:57 - browse：162

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Do digital therapeutics have a future in medicine?

hotspot

entertainment

focus

Theremovalofsmallamountsofbraintissuefromdesperatelyillpatients,doneaspartofaMountSinairesearchproje

WSS

Novo Nordisk to expand supply of Wegovy for U.S. patients

SAMSHA loosens regulations on methadone treatment centers

Study: AI not yet building 'n

H5N1 bird flu: what we're starting to learn about infection in cows

Bird flu outbreak in cows is latest avian flu curveball

Use wet bulb globe temperature, not heat index, to protect workers

focus

knowledge

hotspot

Dobbs anniversary: the lost opportunity of abortion as health care

Dairy farmers resist CDC push for PPE against bird flu virus

Psychedelics group wrestles with new pharma identity

Use wet bulb globe temperature, not heat index, to protect workers

In age of alternative facts, a scholarly course on calling out crap

Telehealth startups turn to complex chronic diseases

FDA approval of Sarepta Duchenne genetic therapy gives me hope

ARCH Venture Partners is raising $3 billion for a life sciences fund

Virginia high school admissions case could be legal follow

What nurses really want: sufficient staffing for patient care

hotspot

Study: Adult vaccinations pay for themselves in societal benefits

Covid misinformation case heads to Supreme Court

Vertex non

New Ultima Genomics DNA sequencer can read genome for $100

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

CDC wastewater surveillance dashboard to track bird flu hotspots

hotspot

entertainment

focus

focus